Soligenix, Inc. Share Price
NASDAQ: SNGX | Micro CapSoligenix, Inc. Stock Performance
Soligenix, Inc. Share Price Chart
Soligenix, Inc. Quarterly Profit & Loss
All figures in USD
Soligenix, Inc. Annual Profit & Loss
All figures in USD
About Soligenix, Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Soligenix, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $0.36 | $0.37 | +2.76% |
Sep 2026 | $0.38 | $0.36 | -10.84% |
Aug 2026 | $0.37 | $0.41 | +9.14% |
Jul 2026 | $0.41 | $0.37 | -7.69% |
Jun 2026 | $0.84 | $0.40 | -56.29% |
May 2026 | $0.35 | $0.92 | +163.43% |
Apr 2026 | $1.21 | $0.35 | -70.34% |
Mar 2026 | $1.15 | $1.18 | +0.00% |
Feb 2026 | $1.25 | $1.18 | -5.60% |
Jan 2026 | $1.36 | $1.25 | -6.72% |
Dec 2025 | $1.57 | $1.34 | -15.99% |
Nov 2025 | $1.49 | $1.59 | +2.90% |